ELTX vs MRNA
ELTX: Elicio Therapeutics is developing lymph node-targeted, off-the-shelf immunotherapies for mKRAS-driven solid tumors using its proprietary AMP technology platform. MRNA: Moderna is a pioneer in mRNA technology, working to transform medicine by developing a broad pipeline of prophylactic vaccines and therapeutic medicines.
Side-by-side fundamentals
| Metric | ELTX | MRNA | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $1.81 | $197.00 | |
| Market cap | $35M | $78.6B | |
| Net margin | -1225.9% | -145.2% | MRNA higher |
| Operating margin | -1031.4% | -158.1% | MRNA higher |
| ROE FY2025, SEC XBRL | -2418.8% | -32.6% | MRNA higher |
| ROA FY2025, SEC XBRL | -153.0% | -22.9% | MRNA higher |
| Debt / equity as of 2026-09-03 | 5.75 | 0.09 | MRNA lower |
| Revenue growth (YoY) as of 2026-09-03 | -91.9% | -27.6% | MRNA higher |
| Revenue CAGR (3y) SEC XBRL | -10.6% | -53.4% | ELTX higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 0.51 | 1.39 | |
| 1-year return as of 2026-10-08 close | -82.8% | +605.6% | MRNA higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.